Latest stories on AXSM
Axsome Therapeutics price target lowered to $238 from $258 at Piper Sandler
The Fly34 · bearishanalyst
Axsome Therapeutics Needs Auvelity Growth To Outrun Launch Costs
Seeking Alpha48 · neutralanalyst
Mizuho reiterates Outperform on Axsome stock ahead of earnings
Investing.com Analyst Ratings61 · neutralanalyst
RBC Capital reiterates Axsome Therapeutics stock rating at Outperform
Investing.com Analyst Ratings58 · neutralanalyst
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?
Yahoo Top50 · neutralgeneral
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?
The Motley Fool64 · neutralproduct/pr
Axsome Therapeutics price target lowered to $295 from $297 at RBC Capital
The Fly44 · neutralanalyst
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?
The Motley Fool55 · neutralanalyst
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
Business Insider50 · neutralgeneral
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
GlobeNewswire50 · neutralearnings
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
The Motley Fool54 · neutralanalyst
Axsome Therapeutics options flow shows heavy put skew ahead of binary catalyst
Investing.com Markets38 · neutralgeneral
Axsome Therapeutics price target lowered to $267 from $280 at Deutsche Bank
The Fly42 · neutralanalyst
H.C. Wainwright reiterates Axsome stock Buy rating at $290 target
Investing.com Analyst Ratings61 · neutralanalyst
Axsome Therapeutics assumed with a Buy at Truist
The Fly61 · neutralanalyst
Truist initiates Axsome stock coverage with buy rating on growth
Investing.com Analyst Ratings61 · neutralanalyst
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction
Yahoo Finance67 · bullishproduct/pr
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
Yahoo Finance67 · bullishproduct/pr
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?
Yahoo Top57 · neutralanalyst
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?
The Motley Fool57 · neutralanalyst
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo Top54 · neutralanalyst
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool54 · neutralanalyst
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool54 · neutralanalyst